Breaking News Bar

Business News and Information

BullMarket.com Updates Outlook on Swine Flu Stocks

PRINCETON, N.J., July 24 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of swine-flu stocks, including Baxter International (NYSE: BAX), Novartis (Nasdaq: NVS), AstraZeneca (NYSE: AZN), BioCryst Pharmaceuticals (Nasdaq: BCRX), Novavax (Nasdaq: NVAX), and Hemispherx BioPharma (NYSE: HEB),among others.

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which outperformed the S&P 500 by 15% in 2008 and was up over 16% year to date at the end of June.

Start your 14-day free trial today:

https://www.bullmarket.com/subscribe/pr/?refer=BMR601P

In its daily report, BullMarket.com wrote: "The swine flu pandemic -- yes, health officials believe we remain in the midst of one -- has faded from the view of many people, but there have been some disturbing reports of late that could have an impact on both your health and your portfolio."

BullMarket.com looked at the following topics, among others:

-- What recent data suggests swine flu stocks could go on another speculation-filled run this fall?

-- Which of the small-cap swine flu stocks looks most interesting?

-- Do any of the large-cap swine flu stocks look like good investments?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Marcie Martin, Bull Market Report, +1-888-278-5515

SOURCE Indie Research Advisors, LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear